New drug trial targets rare blood disorder in untreated patients
Disease control
Not yet recruiting
This study is testing an investigational drug called SLN12140 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have never taken a complement inhibitor medication. The main goal is to see if SLN12140 can safely reduce the destruction of red blood cells, which is the c…
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC